Reaction Details Report a problem with these data
Target
fMet-Leu-Phe receptor
Ligand
BDBM40404
Substrate
n/a
Meas. Tech.
Formylpeptide Receptor (FPR) Ligand Structure Activity Relationship (SAR) Analysis : Dose Response Assay
IC50
500±n/a nM
Citation
 PubChem, PC Formylpeptide Receptor (FPR) Ligand Structure Activity Relationship (SAR) Analysis : Dose Response Assay PubChem Bioassay (2007)[AID] 
Target
Name:
fMet-Leu-Phe receptor
Synonyms:
FPR | FPR1 | FPR1_HUMAN | Formyl peptide Receptor | N-formyl peptide receptor 1 | N-formylpeptide chemoattractant receptor | fMLP receptor | fMet-Leu-Phe receptor | formyl peptide receptor 1
Type:
Enzyme Catalytic Domain
Mol. Mass.:
38456.14
Organism:
Homo sapiens (Human)
Description:
gi_4503779
Residue:
350
Sequence:
METNSSLPTNISGGTPAVSAGYLFLDIITYLVFAVTFVLGVLGNGLVIWVAGFRMTHTVTTISYLNLAVADFCFTSTLPFFMVRKAMGGHWPFGWFLCKFVFTIVDINLFGSVFLIALIALDRCVCVLHPVWTQNHRTVSLAKKVIIGPWVMALLLTLPVIIRVTTVPGKTGTVACTFNFSPWTNDPKERINVAVAMLTVRGIIRFIIGFSAPMSIVAVSYGLIATKIHKQGLIKSSRPLRVLSFVAAAFFLCWSPYQVVALIATVRIRELLQGMYKEIGIAVDVTSALAFFNSCLNPMLYVFMGQDFRERLIHALPASLERALTEDSTQTSDTATNSTLPSAEVELQAK
  
Inhibitor
Name:
BDBM40404
Synonyms:
UNM000003536701 | [6-ethyl-2-methyl-3-(1-methylbenzimidazol-2-yl)-4-oxidanylidene-chromen-7-yl] ethanoate | [6-ethyl-2-methyl-3-(1-methylbenzimidazol-2-yl)-4-oxochromen-7-yl] acetate | acetic acid [6-ethyl-2-methyl-3-(1-methyl-2-benzimidazolyl)-4-oxo-1-benzopyran-7-yl] ester | acetic acid [6-ethyl-4-keto-2-methyl-3-(1-methylbenzimidazol-2-yl)chromen-7-yl] ester | cid_3092570
Type:
Small organic molecule
Emp. Form.:
C22H20N2O4
Mol. Mass.:
376.4052
SMILES:
CCc1cc2c(cc1OC(C)=O)oc(C)c(-c1nc3ccccc3n1C)c2=O |(15.91,-2.7,;15.92,-1.16,;14.59,-.39,;13.19,-1.18,;11.82,-.36,;11.82,1.18,;13.19,2.01,;14.59,1.22,;15.92,1.99,;15.91,3.53,;17.24,4.31,;14.58,4.3,;10.48,1.95,;9.15,1.18,;7.82,1.95,;9.15,-.36,;7.82,-1.13,;6.42,-.5,;5.39,-1.64,;3.85,-1.64,;3.08,-2.97,;3.85,-4.31,;5.39,-4.31,;6.16,-2.97,;7.66,-2.65,;8.8,-3.68,;10.48,-1.13,;10.48,-2.67,)|
Structure:
Search PDB for entries with ligand similarity: